ALMA Life Sciences

ALMA Life Sciences focuses on early-stage life science companies. This typically includes pre-clinical and Phase I/II therapeutics developers, pre-revenue medical device firms, and seed-to-Series A digital health platforms. No later-stage or growth-equity mandates have been disclosed, and the firm has not publicized any public-market crossover or PIPE activity.

The firm invests across life sciences broadly, including biopharma, medical devices, diagnostics, research tools and digital health. As a La Jolla-based specialist, it benefits from proximity to the San Diego biotech cluster, which is a hub for genomics, oncology and immunology startups, though no specific therapeutic-area preference has been publicly stated.

ALMA Life Sciences does not publicly disclose the names of its principals, investment committee members or senior leadership. The firm maintains a deliberately low public profile, with no partner biographies, LinkedIn presence or media interviews available to identify the decision-makers or their prior investment track records.

The firm's disclosed strategy centers on direct early-stage equity investments. There is no public record of ALMA Life Sciences acting as a limited partner in other venture funds, participating in special purpose vehicles or operating as a fund-of-funds. The vehicle structure — whether a traditional closed-end fund or a holding company — has not been disclosed.

Sourcing channels are not publicly described. Given the firm's La Jolla location and early-stage mandate, its deal flow likely stems from relationships with academic institutions (UC San Diego, Salk, Scripps Research), regional incubators, and scientific founder networks. No proprietary sourcing platform or external advisory network has been cited.

The firm has not publicized any co-investment activity or partnerships with external general partners. Its small, insider-capital structure suggests deals are likely fully self-funded rounds rather than club deals or syndicated participations alongside larger institutional investors.

No philanthropic foundations, donor-advised funds, real-asset arms or parallel investment vehicles have been disclosed in association with ALMA Life Sciences. The firm appears to operate as a single-entity investment platform without any publicly reported adjacent structures.